SCHEMBL25529183

SCHEMBL25529183

O=C(O)c1cccn(-c2ccnc(O)c2)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.38
TDP1 Q9NUW8 2/20 0.38
POLB P06746 2/20 0.38
APEX1 P27695 1/20 0.38
KDM4E B2RXH2 7/20 0.37
KDM4A O75164 2/20 0.37
EGLN1 Q9GZT9 2/20 0.37
RAB9A P51151 1/20 0.37
HIF1AN Q9NWT6 1/20 0.37
MET P08581 4/20 0.37
HSD17B10 Q99714 2/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CYP3A4 P08684 1/20 0.36
MAPT P10636 1/20 0.36
ALOX15 P16050 1/20 0.36
TSHR P16473 1/20 0.36
BLM P54132 1/20 0.36
AGER Q15109 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30174311 0.86 MAPK1 (0.38) L3MBTL1KDM4EMETALDH1A1CYP3A4
SCHEMBL25529181 0.81 KDM4E (0.40) TDP1POLBKDM4EMETALDH1A1
SCHEMBL25233228 0.80 RIPK3 (0.45) L3MBTL1TDP1POLBAPEX1KDM4E
SCHEMBL1137068 0.76 KDM4E (0.54) L3MBTL1TDP1POLBAPEX1KDM4E
SCHEMBL10517562 0.75 ESR1 (0.46) L3MBTL1TDP1POLBAPEX1KDM4E
SCHEMBL4812121 0.75 ALDH1A1 (0.43) L3MBTL1TDP1POLBAPEX1KDM4E
SCHEMBL5759739 0.74 NOTUM (0.52) L3MBTL1POLBKDM4EALDH1A1MAPT
SCHEMBL4430908 0.74 ALDH1A1 (0.51) L3MBTL1TDP1POLBAPEX1KDM4E
SCHEMBL25217521 0.73 MYC (0.52) L3MBTL1TDP1POLBKDM4EHSD17B10
SCHEMBL30367555 0.72 TYK2 (0.50) L3MBTL1TDP1POLBAPEX1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 US disclosed
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151003-A1 COMPOUNDS AND METHODS OF USE PRKACB, PRKACA, PRKX L3MBTL1 3091/4885TDP1 612/4885POLB 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.